Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-7117 (Dersimelagon) in diffuse cutaneous systemic sclerosis
NCT04440592Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Feb 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of dersimelagon in diffuse cutaneous systemic sclerosis (dcSSc), sponsored by Mitsubishi Tanabe Pharma Corporation. Started Feb 2021; status: completed.
02
Drugs
dersimelagon
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT04440592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04440592.